^
    Back
    Association details:
    Biomarker:FGFR2-BICC1 fusion
    Cancer:Cholangiocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Pemazyre (pemigatinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Front Immunol
    Title:

    Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma

    Published date:
    05/24/2023
    Excerpt:
    A 34-year-old female was diagnosed with advanced iCCA...An FGFR2-BICC1 gene fusion was found in this patient….she is currently receiving chemotherapy, pemigatinib, and pembrolizumab treatment again. She regained an excellent physical status after 16 months of treatment. To the best of our knowledge, this was the first reported case of advanced iCCA successfully treated with a combination of pemigatinib, chemotherapy, and ICIs as a first-line regimen. This treatment combination may be effective and safe in the advanced iCCA.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.3389/fimmu.2023.1124482